Eli Lilly and Company today announced the promotion of Aarti Shah, Ph.D., to senior vice president and chief information officer effective July 1. She has been the global brand development leader for immunology since 2013.
Shah joined Lilly in 1994 as a senior statistician after completing her doctorate in applied statistics from the University of California, Riverside. During her career at Lilly, she has held many technical and administrative leadership positions, both in the United States and abroad, including serving as vice president for biometrics and advanced analytics and as executive director of global information sciences.
In her new role, she will lead the efforts of a worldwide IT organization with more than 1,300 employees, in addition to many contractors and external business partners, to deliver innovative IT solutions to the business. She will report to Derica Rice, Lilly’s executive vice president of Global Services and chief financial officer.
“As a visionary and inspirational leader, Aarti has a proven track record of building strong, flexible and sustainable organizations. She is known for her relentless focus and passion for developing people. And her deep knowledge of drug development will be vital as IT touches every aspect of our business,” Rice said.
“I want to create an environment in which IT enables and brings innovative solutions to business transformations across Lilly’s entire drug development value chain from discovery to commercial. I hope to do this by unleashing the potential of our employees and by building strong internal and external collaborations and thus play a critical role in bringing Lilly’s mission to life,” Shah said.
Shah serves on the board of directors for the Indianapolis Public Library Foundation and Center for Interfaith Cooperation and on the Executive Advisory Council for the Healthcare Businesswoman’s Association (HBA) Indiana Chapter. She received the 2011 Rising Star Award from Healthcare Businesswoman’s Association (HBA).
Source: Eli Lilly and Company
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.